Pharmacokinetics of iopentol in patients with chronic renal failure.
Iopentol 350 mg I/ml was injected in doses of 265 to 533 mg I/kg b.w. (mean 417 mg I/kg b.w.) in 10 patients with advanced nondiabetic chronic renal failure (S-creatinine 672 +/- 259 mumol/l (mean +/- SD)). Urine (10 patients) and feces (7 patients) were collected at 24 h intervals for 5 days after the injection. The elimination of iopentol was delayed. Five days after injection a mean of 54% (range 35-79%) of the dose was recovered in urine, and 11% (0-20%) in feces. Mean elimination half-life was 28.4 h, about 14 times the half-life found in healthy volunteers. The apparent volume of distribution was 0.27 l/kg b.w., indicating distribution only to extracellular fluid. Using renal iopentol clearance as reference value, GFR was overestimated by 40 to 60% with iopentol total clearance, showing extrarenal elimination of iopentol. The difference was most pronounced in patients with low GFR. In conclusion, this study shows an extrarenal elimination of iopentol and demonstrates a substantial increase in the fecal elimination in patients with severe renal failure.
Svaland
M G
MG
Research and Development Division, Nycomed AS, Oslo, Norway.
Kolmannskog
F
F
Lillevold
P E
PE
Nordal
K P
KP
Ressem
L
L
Berg
K J
KJ
D000328:Adult; D000368:Aged; D003287:Contrast Media / Q000493:pharmacokinetics*; D005243:Feces / Q000737:chemistry; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008297:Male; D008875:Middle Aged; D014283:Triiodobenzoic Acids / Q000097:blood / Q000493:pharmacokinetics* / Q000652:urine
D003287:Contrast Media; D014283:Triiodobenzoic Acids; C053571:iopentol